In a clinical trial of patients with NSCLC treated with anti–PD-1, mitigating persistent IFN-I and inflammation with a JAK inhibitor decreased terminal differentiation of CD8 T cells and expanded fate-flexible CD8 T cell progenitors in responding patients. Patients with progressive disease had high baseline inflammation that minimally changed with JAK1 inhibition. Credit: Science (2024). DOI: 10.1126/science.adf1329 Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Read More